Who Paid My Doc
Daniel Kueter
Chattanooga, TN Medical Doctor
NPI 1184714180 CMS profile 99752
1010 E 3Rd St, Suite 202, Chattanooga, TN 37403
General payments
$20,583
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Kueter of Chattanooga, TN is reported in the CMS Open Payments database as having received $20,583 across 45 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $8,867 | 14 | |
| 2024 | General | $63 | 2 | |
| 2023 | General | $1,346 | 3 | |
| 2022 | General | $1,642 | 5 | |
| 2021 | General | $2,188 | 4 | |
| 2020 | General | $1,770 | 1 | |
| 2019 | General | $4,708 | 16 |
Beside peers
- Daniel Kueter
- Tennessee median
- Middle half of Tennessee
- National median
In program year 2025, general payments to Daniel Kueter were reported at $8,867. Among 24,836 Tennessee profiles paid that year, the median was $199 and the middle half received between $54 and $728.
Show as a table
| Year | Daniel Kueter | Tennessee median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,708 | $197 | $58–$789 | $163 |
| 2020 | $1,770 | $132 | $38–$484 | $114 |
| 2021 | $2,188 | $145 | $39–$541 | $132 |
| 2022 | $1,642 | $170 | $50–$642 | $149 |
| 2023 | $1,346 | $183 | $50–$668 | $160 |
| 2024 | $63 | $187 | $51–$700 | $164 |
| 2025 | $8,867 | $199 | $54–$728 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
223
Drug cost
$1,601
Branded share of claims
26%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methylprednisolone | Generic | 89 | $659 | |
| Tizanidine Hcl | Generic | 62 | $416 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 33 | $218 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 25 | $215 | |
| Gabapentin | Generic | 14 | $93 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 67 billing codesPaid by Medicare
$255,063
Medicare patients
321
Services billed
879
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 37% | |
| Depression | 35% | |
| Ischemic heart disease | 34% | |
| Chronic kidney disease | 32% | |
| Osteoporosis | 24% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
45 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.